Myasthenia Gravis
Also known as: MG
Myasthenia gravis is a chronic autoimmune neuromuscular disorder in which antibodies block or destroy acetylcholine receptors at the neuromuscular junction, disrupting communication between nerves and muscles. This leads to fluctuating skeletal muscle weakness that worsens with activity and improves with rest. The condition can affect muscles controlling eye movement, facial expression, swallowing, and breathing.
Last updated November 10, 2026
Understanding Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease in which antibodies attack the junction where nerve meets muscle, so that muscles tire with use and recover with rest. It is rare, affecting roughly 14 to 20 people per 100,000, which means somewhere between 50,000 and 70,000 Americans, and it has two peaks: women in their 20s and 30s, and men over 60. Over the last two decades the second peak has grown, and late-onset MG in people over 50 is now the most common form, partly because older people are being diagnosed rather than written off as frail. About 15 percent of patients have weakness confined to the eye muscles (ocular MG), with drooping lids and double vision; the rest have generalized disease affecting the face, throat, neck, limbs or breathing. Of those who start with purely ocular symptoms, half to four-fifths spread to generalized weakness, usually within the first two years.
In 85 percent of generalized cases the target is the acetylcholine receptor (AChR) on the muscle side of the junction. The antibodies block the receptor, pull receptors into the cell to be destroyed, and activate complement, which punches holes in the muscle membrane and flattens the folds that normally hold a dense carpet of receptors. Each nerve impulse still releases acetylcholine, but with fewer working receptors the signal becomes marginal, and after repeated firing it fails, which is why the weakness is fatigable and worse at the end of the day. Five to 8 percent have antibodies to MuSK instead, which tend to cause prominent face, tongue and throat weakness and respond differently to treatment. The thymus gland is the engine in many AChR cases: 60 to 70 percent of young-onset patients have thymic hyperplasia and 10 to 15 percent of all patients have a thymoma. Untreated, MG worsens over the first few years; with treatment most people reach minimal symptoms, though relapses and a 15 to 20 percent lifetime risk of a breathing crisis remain.
Treatment follows the Myasthenia Gravis Foundation of America international consensus guidance (updated 2021). Pyridostigmine, which slows the breakdown of acetylcholine, gives symptom relief within an hour and is enough on its own for some ocular or mild cases. Most generalized patients also need immunosuppression: prednisone brings improvement within weeks but at the cost of bone loss, weight gain, diabetes and infection, so a steroid-sparing drug such as azathioprine or mycophenolate is added, which takes 6 to 12 months to work. Thymectomy is no longer reserved for thymoma. The MGTX trial (2016) randomized 126 AChR-positive patients under 65 to thymectomy plus prednisone or prednisone alone; over three years the surgery group had better strength scores, needed a third less prednisone and had hospitalizations for exacerbations of 9 percent versus 37 percent. For myasthenic crisis, intravenous immunoglobulin or plasma exchange works within days. Since 2017 a new class of targeted drugs, complement inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor blockers (efgartigimod, rozanolixizumab, nipocalimab), has given fast, substantial improvement to patients not controlled on standard therapy.
There is no herb or supplement with evidence that it improves MG, and this page will not pretend otherwise. The useful supplement conversation is about the side effects of treatment and about what to avoid. Anyone on prednisone for more than three months should be taking calcium and vitamin D, because the American College of Rheumatology guideline on steroid-induced bone loss recommends them for every such patient, and a bone density scan is reasonable. Low vitamin D levels are common in MG and one small Swedish study found supplementation improved fatigue scores, but it is far from proven. The avoid list is longer and more important: magnesium supplements and magnesium-containing antacids in large doses can worsen weakness; so can quinine (including tonic water), and the herbs and 'immune support' blends that stimulate immune activity, such as echinacea and astragalus, are a theoretical risk in any autoimmune disease and best skipped. Botulinum toxin injections, including cosmetic ones, are dangerous in MG.
The most common mistake is not recognizing a crisis early. Trouble swallowing saliva, a weak cough, a soft or nasal voice, needing to sit up to breathe, or being unable to count to 20 in one breath all mean the breathing muscles are failing, and the right response is the emergency department, where a bedside breathing test (forced vital capacity) decides whether intensive care is needed. The second mistake is assuming the drug list in your pocket is complete. Several medicines unmask or worsen MG, including fluoroquinolone and macrolide antibiotics, aminoglycosides, beta-blockers, hydroxychloroquine, D-penicillamine, intravenous magnesium and the immune checkpoint inhibitors used in cancer treatment, and every prescriber, dentist and anesthetist needs to know you have MG before writing anything. Carry a card, and check every new prescription against the MGFA cautionary drug list before taking it.
At a Glance
- Common symptoms
- Drooping of one or both eyelids (ptosis), Double vision (diplopia), Difficulty speaking (dysarthria)
- Main treatments
- Acetylcholinesterase inhibitors (pyridostigmine), Immunosuppressive medications (prednisone, azathioprine, mycophenolate), Thymectomy (surgical removal of the thymus gland)
- Category
- Autoimmune · About 14–20 per 100,000 people in the United States
- See a doctor if
- Progressive muscle weakness, especially in the eyes, face, or throat
Symptoms
Causes
- Autoimmune antibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK)
- Thymus gland abnormalities (thymoma or thymic hyperplasia)
- Genetic susceptibility factors
Risk Factors
- Women under 40 and men over 60 (bimodal age distribution)
- Thymus gland tumors (thymoma)
- Family history of autoimmune disease
- Other autoimmune conditions (thyroid disease, rheumatoid arthritis, lupus)
Diagnosis
- Acetylcholine receptor antibody test (positive in ~85% of generalized MG)
- Anti-MuSK antibody test if AChR antibodies are negative
- Edrophonium (Tensilon) test or ice pack test
- Repetitive nerve stimulation showing decremental response
- CT or MRI of the chest to evaluate the thymus gland
Treatment
- Acetylcholinesterase inhibitors (pyridostigmine)
- Immunosuppressive medications (prednisone, azathioprine, mycophenolate)
- Thymectomy (surgical removal of the thymus gland)
- Plasmapheresis or IVIG for acute exacerbations or myasthenic crisis
- Monoclonal antibodies (eculizumab, efgartigimod) for refractory cases
Natural remedies for myasthenia gravis: what the evidence says
Ranked by the strength of human evidence for myasthenia gravis specifically. These sit alongside medical care, not in place of it.
Vitamin D
Preliminary evidencePeople with MG have lower vitamin D levels than matched controls in several studies, and in a Swedish pilot study of 33 patients, 16 with low levels who took 800 IU daily for about 2.5 months improved their fatigue scores by roughly a third while untreated patients did not. That is one small, uncontrolled study, so vitamin D cannot be said to treat MG. The firmer reason to take it is bone protection on prednisone: the 2022 American College of Rheumatology guideline recommends 600 to 800 IU daily for everyone on glucocorticoids for 3 months or longer.
- Studied dose
- 800 to 2,000 IU vitamin D3 daily, adjusted to keep a blood level above 30 ng/mL; ask for a vitamin D test at diagnosis and yearly on steroids.
- Cautions
- Do not exceed 4,000 IU daily without blood-level monitoring. Thiazide diuretics raise calcium further when combined with vitamin D, and people with sarcoidosis or kidney stones need medical supervision.
Calcium
Moderate evidenceCalcium does nothing for the muscle weakness of MG; its evidence is for the bone loss that prednisone causes, which starts within the first 3 months and raises fracture risk by 30 to 50 percent at common MG doses. A 2000 Cochrane review of 5 trials (274 people) found calcium plus vitamin D prevented lumbar spine and forearm bone loss in people on steroids, and the American College of Rheumatology guideline recommends 1,000 to 1,200 mg daily, from diet plus supplements, for anyone on 2.5 mg or more of prednisone for 3 months or longer.
- Studied dose
- 1,000 to 1,200 mg elemental calcium daily counting food, split into doses of no more than 500 mg, as carbonate with meals or citrate at any time.
- Cautions
- Separate from levothyroxine, iron and quinolone or tetracycline antibiotics by 2 to 4 hours. Avoid calcium products combined with magnesium, since magnesium can worsen MG weakness, and keep total calcium under 2,000 mg daily to limit kidney stone risk.
What matters day to day
- Schedule demanding tasks for the morning or 30 to 60 minutes after a pyridostigmine dose: MG weakness builds with use through the day, and timing activity around the drug's peak is the single most effective self-management habit.
- Keep exercising, gently and consistently: in a 2017 Dutch study, 11 stable patients tolerated 12 weeks of strength and aerobic training without worsening, and supervised programs improve stamina and mood; stop if a session leaves you weaker the next day rather than just tired.
- Treat every infection promptly and get the inactivated flu, COVID-19 and pneumococcal vaccines: infection is the trigger in about 1 in 3 myasthenic crises, and the vaccines are safe in MG, though live vaccines need to be checked with your neurologist if you are immunosuppressed.
- Keep cool in hot weather and avoid hot baths: heat slows nerve transmission at the junction, and many patients can measure their weakness getting worse above about 85 degrees F.
- Eat when your swallowing is strongest, usually soon after a pyridostigmine dose, choose soft moist foods on bad days, and sit upright for meals: choking and aspiration pneumonia are common ways a mild exacerbation becomes a hospital stay.
- Ask for a TSH at diagnosis and every year or two: autoimmune thyroid disease occurs in about 1 in 10 people with MG, and both an over- and underactive thyroid make weakness worse.
Prevention
- No known prevention for myasthenia gravis
- Avoiding known triggers such as stress, illness, certain medications
- Regular follow-up with a neurologist to adjust therapy
When to See a Doctor
- Progressive muscle weakness, especially in the eyes, face, or throat
- Difficulty breathing or swallowing (emergency — myasthenic crisis)
- Worsening of symptoms despite current treatment
- New medication causing muscle weakness (certain antibiotics, beta-blockers)
Frequently Asked Questions
References
- Narayanaswami P, Sanders DB, Wolfe G, et al.. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology (2021)
- Wolfe GI, Kaminski HJ, Aban IB, et al.. Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine (2016)
- Gilhus NE, Tzartos S, Evoli A, et al.. Myasthenia gravis. Nature Reviews Disease Primers (2019)
- Howard JF Jr, Utsugisawa K, Benatar M, et al.. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology (2017)
- Howard JF Jr, Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology (2021)
- Askmark H, Haggard L, Nygren I, Punga AR. Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: a pilot study. European Journal of Neurology (2012)
- Humphrey MB, Russell L, Danila MI, et al.. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatology (2023)
- National Institute of Neurological Disorders and Stroke. Myasthenia Gravis (2024)View source
- Mayo Clinic. Myasthenia gravis (2024)View source
Related Conditions
Have questions about Myasthenia Gravis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.